On March 24, 2025, Harmony Biosciences announced the departure of Chief Commercial Officer Jeffrey Dierks effective March 31, 2025, and appointed Adam Zaeske as his replacement, effective the same date; Dierks will receive $476,215 and accelerated vesting of stock options as part of his separation agreement dated March 20, 2025.